Zymeworks Inc

NYSE:ZYME   2:43:00 PM EDT
29.97
+1.38 (+4.83%)
Products, Regulatory

Exelixis In Licenses Iconic Therapeutics' Tissue Factor-Targeting Antibody-Drug Conjugate Ahead Of Planned Investigational New Drug Application

Published: 12/02/2020 13:20 GMT
Zymeworks Inc (ZYME) - Exelixis In-licenses Iconic Therapeutics' Tissue Factor-targeting Antibody-drug Conjugate Ahead of Planned Investigational New Drug Application.
Exelixis Inc - Phase 1 Clinical Trial Planned for Early 2021, Pending FDA's Acceptance of Exelixis' Planned Ind Filing.
Exelixis Inc - Made an Option Exercise Payment of $20 Million to Iconic Therapeutics.